The spin-off company INBRAIN Neuroelectronics, an innovative graphene-based neural network platform developer, has appointed a Nobel Laureate, and experts in artificial intelligence, neuroscience, and neuroethics to shape and realise its vision for the future of 2D materials.
INBRAIN Neuroelectronics S.L., a company at the intersection of medtech, deeptech, and digital health dedicated to developing the world’s first intelligent graphene-neural platform, has announced the appointment of a scientific advisory board. This fast-growing spin-off company was founded in 2020 by researchers from the Catalan Institute of Nanoscience and Nanotechnology (ICN2), a BIST centre, the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), and ICREA.
The board’s inaugural members include Nobel Laureate and graphene pioneer Konstantin Novoselov, Ph.D., FRS, FInstP, FRSC, from the National University of Singapore; artificial intelligence (AI) expert Richard Benjamins, Ph.D., from Telefonica and OdiseIA; renowned neuroscientist David Eagleman, Ph.D., from Stanford University; and Jennifer A. Chandler, LLB, LLM, from the University of Ottawa, a foremost authority on biomedical ethics and their legal implications for neurotech. The board will use its collective expertise to guide INBRAIN’s vision into the evolution of 2D materials such as graphene in clinical neurotechnology, providing insights on the latest developments in neuroscience, neuroethics, neurorights, and the impact of AI in neurobiology.
The technology developed at INBRAIN harnesses the power of graphene, a two-dimensional material first isolated in 2004 and made of a lattice of carbon atoms only one atom thick. The strongest material ever tested, being roughly 100 times stronger than the equivalent thickness of steel, graphene has unique electrical and thermal conduction properties. The neural platform technology enables ultra-high signal resolution at levels never seen before. The INBRAIN system’s machine learning software detects therapy-specific biomarkers to deliver highly focused, adaptive neuroelectronic therapy that is personalised for each patient.
‘The INBRAIN mission centres on leveraging new discoveries in materials science, and transforming them into safe and effective neural interfaces to improve the lives of patients with conditions affecting the central and peripheral nervous systems,” said INBRAIN Neuroelectronics Co-founder & CEO Dr. Carolina Aguilar.
“Our newly established board will be critical in helping us navigate the scientific and ethical challenges posed by our exploration of this new frontier in neurotech,” added INBRAIN Neuroelectronics Co-Founder and Scientific Advisory Board chair Prof. Kostas Kostarelos, Ph.D., professor and group leader at the University of Manchester and the Catalan Institute of Nanoscience and Nanotechnology (ICN2).
About INBRAIN Neuroelectronics
INBRAIN Neuroelectronics S.L., founded in 2020, is a medical device company dedicated to developing the world’s first intelligent graphene-neural platform to treat a variety of conditions. INBRAIN’s first product is designed to decode and modulate brain activity in high resolution, using artificial intelligence to trigger adaptive responses for personalised neurological treatment of epilepsy, Parkinson’s disease, and aphasia (speech impairment).
Among its founders are ICREA Prof. Jose A. Garrido, leader of the ICN2 Advanced Electronic Materials and Devices Group, Prof. Kostas Kostarelos, leader of the ICN2 Nanomedicine Group and Professor and Chair of Nanomedicine at the National Graphene Institute and the Faculty of Biology, Medicine and Health at the University of Manchester (UK), and Dr. Anton Guimerà, staff researcher in the IMB-CNM-CSIC Biomedical Applications Group.
Learn more:
ICN2 news piece
INBRAIN Neuroelectronics website